secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107747
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma reports Q3 net loss of $3.9M, raises up to $105.3M in private placement
--------------------------------------------------------------------------------

- Net loss of $3.9M for Q3 2025 ($11.5M YTD) vs $2.3M and $6.7M in prior-year periods; R&D spend increased to $2.3M for Q3.
- Cash, equivalents, and marketable securities totaled $5.4M as of Sept 30; Oct 2025 added $16.6M upfront from private placement, extending runway into 2027.
- Private placement financing closed Oct 2025 with potential gross proceeds up to $105.3M including warrants exercise.
- Sally Lawlor appointed CFO; FDA granted Orphan Drug Designation for QRX003 for Netherton Syndrome; pivotal studies to start Q4 2025.
- NETHERTON NOW campaign surpassed 1.5M video views since Feb 2025; positive Peeling Skin Syndrome data released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925107747/0001104659-25-107747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925107747/tm2530187d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer